What is the long-term trend for Thermo Fisher Scientific's specialty diagnostics — acquisitions?

Over 4 years (2021 to 2025), Thermo Fisher Scientific's specialty diagnostics — acquisitions has grown at a -100.0% compound annual growth rate (CAGR), from $8M to $0.

What does specialty diagnostics — acquisitions mean?

The total capital expenditure allocated to the purchase of external businesses or product lines specifically integrated into the Specialty Diagnostics division. This metric tracks the inorganic growth strategy and the expansion of the segment's diagnostic capabilities.

Thermo Fisher Scientific (TMO) Specialty Diagnostics — Acquisitions

Screener

Other segment segments

Life Sciences Solutions

$2.1B-8.7%

Laboratory Products and Biopharma Services

$15M—

Analytical Instruments

$0—

Similar metrics at other companies

APGSpecialty Services — Acquisitions

$0—

HDOther — Acquisitions

$109M+419%

HPQPrinting — Acquisitions

$0-100%

UNHUnitedHealthcare — Acquisitions

$0—

CSCOAmericas — Acquisitions

$18M-18.2%

LZBRetail — Acquisitions

$14.41M+275%

Other financials

Income statement

See full

Revenue$12.0B—

Operating income$2.1B—

Net income$1.7B+7.4%

EPS (diluted)$4.68+9.3%

Balance sheet

See full

Cash & equivalents$4.1B-11.7%

Total debt$39.2B+4.6%

Total equity$52.7B+4.3%

Total assets$113.17B+11.8%

Cash flow

See full

Operating cash flow$2.1B+51.9%

CapEx-$1.2B-509%

Free cash flow$923.0M-16.5%

Valuation

See full

Market cap$213.65B+26.0%

Enterprise value$248.77B+22.9%

P/E30.7×+4.9×

P/S4.8×-0.9×

Profitability

See full

Gross margin58.3%—

Operating margin17.2%+0.8pp

Net margin15.2%+1.0pp

FCF margin15.7%-2.1pp

Returns & leverage

See full

Return on equity13.5%+0.1pp

Debt / equity0.7×0.0×

Current ratio1.6×-0.4×

Where this comes from

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The source filing: Thermo Fisher Scientific’s 10-K, filed February 26, 2026.

Filed: Feb 26, 2026, 12:11 PM EST
Fiscal year: FY2025
Accession: 0000097745-26-000018

(In millions)	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Total
Balance at December 31, 2023	$10,151	$5,051	$4,923	$23,895	$44,020
Acquisitions	2,302	—	—	—	2,302
Currency translation	(117)	(92)	(139)	(122)	(470)
Balance at December 31, 2024	12,336	4,959	4,784	23,773	45,853
Acquisitions	2,101	—	—	15	2,117
Currency translation	473	184	292	444	1,393
Balance at December 31, 2025	$14,910	$5,143	$5,076	$24,232	$49,362

Item 8. Financial Statements and Supplementary Data

FAQ

What is Thermo Fisher Scientific's specialty diagnostics — acquisitions?: Thermo Fisher Scientific (TMO) reported specialty diagnostics — acquisitions of $0 in Q4 2025.
What is the long-term trend for Thermo Fisher Scientific's specialty diagnostics — acquisitions?: Over 4 years (2021 to 2025), Thermo Fisher Scientific's specialty diagnostics — acquisitions has grown at a -100.0% compound annual growth rate (CAGR), from $8M to $0.
What does specialty diagnostics — acquisitions mean?: The total capital expenditure allocated to the purchase of external businesses or product lines specifically integrated into the Specialty Diagnostics division. This metric tracks the inorganic growth strategy and the expansion of the segment's diagnostic capabilities.